Mechanisms of new targeted drugs in follicular lymphoma and clinical options
10.3760/cma.j.cn115356-20201202-00289
- VernacularTitle:滤泡淋巴瘤新靶向药物治疗机制与临床选择
- Author:
Xiaomeng FENG
1
;
Ou BAI
Author Information
1. 吉林大学第一医院血液科，长春 130000
- Keywords:
Lymphoma, follicular;
Drug therapy, combination;
Tissue therapy;
Immunomodulation
- From:
Journal of Leukemia & Lymphoma
2021;30(7):441-444
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma is the most common indolent lymphoma. At present, it is commonly treated with immunochemotherapy, but the prognosis of patients with progression and relapse is still poor. New targeted drugs include cell surface antibodies, immunomodulators, cell signaling pathway kinase inhibitors, and chimeric antigen receptor T cell therapy and dendritic cell vaccines have greatly extended the survival period of these patients and provided more options for clinical treatment.
